Zacks Research Has Pessimistic View of RDY Q3 Earnings

Dr. Reddy’s Laboratories Ltd (NYSE:RDY) – Equities researchers at Zacks Research cut their Q3 2026 earnings per share (EPS) estimates for shares of Dr. Reddy’s Laboratories in a report released on Friday, November 14th. Zacks Research analyst Team now anticipates that the company will post earnings of $0.16 per share for the quarter, down from their previous forecast of $0.18. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $0.80 per share. Zacks Research also issued estimates for Dr. Reddy’s Laboratories’ Q4 2026 earnings at $0.14 EPS, FY2026 earnings at $0.69 EPS, Q2 2027 earnings at $0.16 EPS, Q4 2027 earnings at $0.10 EPS, FY2027 earnings at $0.55 EPS and Q2 2028 earnings at $0.16 EPS.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its earnings results on Friday, October 24th. The company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of $0.18 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.13% and a net margin of 17.14%.The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $944.26 million.

Separately, Weiss Ratings reissued a “buy (b-)” rating on shares of Dr. Reddy’s Laboratories in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $16.90.

Dr. Reddy’s Laboratories Stock Up 0.3%

Shares of NYSE:RDY opened at $13.98 on Monday. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $11.67 billion, a P/E ratio of 17.25, a P/E/G ratio of 6.22 and a beta of 0.37. Dr. Reddy’s Laboratories has a 52-week low of $12.26 and a 52-week high of $16.17. The stock’s fifty day simple moving average is $14.19 and its 200-day simple moving average is $14.42.

Institutional Investors Weigh In On Dr. Reddy’s Laboratories

A number of hedge funds and other institutional investors have recently made changes to their positions in RDY. Zurich Insurance Group Ltd FI lifted its position in Dr. Reddy’s Laboratories by 19.0% during the third quarter. Zurich Insurance Group Ltd FI now owns 191,397 shares of the company’s stock worth $2,676,000 after buying an additional 30,527 shares during the period. Citadel Advisors LLC increased its stake in shares of Dr. Reddy’s Laboratories by 34.0% during the 3rd quarter. Citadel Advisors LLC now owns 134,282 shares of the company’s stock valued at $1,877,000 after acquiring an additional 34,080 shares during the last quarter. Aquatic Capital Management LLC increased its stake in shares of Dr. Reddy’s Laboratories by 2.3% during the 3rd quarter. Aquatic Capital Management LLC now owns 68,168 shares of the company’s stock valued at $953,000 after acquiring an additional 1,536 shares during the last quarter. Ameriprise Financial Inc. lifted its holdings in shares of Dr. Reddy’s Laboratories by 20.9% during the 3rd quarter. Ameriprise Financial Inc. now owns 22,125 shares of the company’s stock worth $309,000 after acquiring an additional 3,825 shares during the period. Finally, Creative Planning boosted its position in shares of Dr. Reddy’s Laboratories by 15.3% in the third quarter. Creative Planning now owns 1,262,891 shares of the company’s stock worth $17,655,000 after acquiring an additional 167,959 shares during the last quarter. Hedge funds and other institutional investors own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.